Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05477589 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML

Study acronym: SCRIPT-AML
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 3 of 17 sitesv3
  2. Site details revised at 1 of 17 sitesv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
It is a randomized phase 3 study comparing two conditioning regimens in children with Acute Myeloid Leukemia, AML, undergoing allogenic stem cell transplantation. The primary aim is to investigate if a conditioning regimen containing one alkylator (Bu) combined with two antimetabolites (Clo and Flu) results in superior 2-year acute grade III to IV-free, chronic non-limited GvHD-free, relapse free survival than a conditioning regimen combining three alkylating agents (BuCyMel)
Trial Details
NCT Number NCT05477589
Lead Sponsor Vastra Gotaland Region
Conditions
(from sponsor)		 Acute Myeloid Leukemia (AML) in Remission, Stem Cell Transplantation
Related terms Leukemia, Leukemia, Myeloid, Acute, Neoplasms
Enrollment 170 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov